Transgene (company)

Transgene was founded in 1979, on the initiative of Pierre Chambon and Philippe Kourilsky. Jean-Pierre Lecocq was the first Scientific Director of Transgene in 1980.{{Cite book|last1=Lathe|first1=Richard|url=https://www.intechopen.com/online-first/76468|title=The Early Development of the Vaccinia–Rabies Recombinant Vaccine Raboral®|last2=Kieny|first2=Marie Paule|date=2021-04-26|publisher=IntechOpen|isbn=978-1-83969-230-7|language=en}}

Dr Alessandro Riva, MD, joined Transgene in 2022 as Chairman of the Board of Directors. In May 2023 the board appointed him Chairman adn Chief Executive Officer of the company{{Cite news |title=Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy |url=https://www.businesswire.com/news/home/20231205509214/en/Transgene-Strengthens-its-Leadership-Team-to-Accelerate-its-Growth-Strategy |archive-url=http://web.archive.org/web/20231205184244/https://www.businesswire.com/news/home/20231205509214/en/Transgene-Strengthens-its-Leadership-Team-to-Accelerate-its-Growth-Strategy |archive-date=2023-12-05 |access-date=2024-12-26 |language=en}}^,.{{Cite news |date=2023-10-12 |title=French biotech company posts promising results for cancer vaccines |url=https://www.lemonde.fr/en/france/article/2023/10/12/french-biotech-company-posts-promising-results-for-cancer-vaccines_6167951_7.html |access-date=2024-12-26 |language=en}}

Transgene owns two technological platforms:

• Invir.IO is a technology platform based on the patented oncolytic viruses that replicate only in cancer cells. The genome of these viruses has been modified to express anti-tumor therapies directly within the tumor.{{cite journal |last1=Foloppe |first1=Johann |last2=Kempf |first2=Juliette |last3=Futin |first3=Nicolas |last4=Kintz |first4=Jacqueline |last5=Cordier |first5=Pascale |last6=Pichon |first6=Christelle |last7=Findeli |first7=Annie |last8=Vorburger |first8=Fabien |last9=Quemeneur |first9=Eric |last10=Erbs |first10=Philippe |title=The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism |journal=Molecular Therapy - Oncolytics |date=September 2019 |volume=14 |pages=1–14 |doi=10.1016/j.omto.2019.03.005 |pmid=31011628 |pmc=6461584 }}{{cite journal |last1=Gallardo |first1=Franck |last2=Schmitt |first2=Doris |last3=Brandely |first3=Renée |last4=Brua |first4=Catherine |last5=Silvestre |first5=Nathalie |last6=Findeli |first6=Annie |last7=Foloppe |first7=Johann |last8=Top |first8=Sokunthea |last9=Kappler-Gratias |first9=Sandrine |last10=Quentin-Froignant |first10=Charlotte |last11=Morin |first11=Renaud |last12=Lagarde |first12=Jean-Michel |last13=Bystricky |first13=Kerstin |last14=Bertagnoli |first14=Stéphane |last15=Erbs |first15=Philippe |title=Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators |journal=Biomedicines |date=26 November 2020 |volume=8 |issue=12 |pages=543 |doi=10.3390/biomedicines8120543 |pmid=33256205 |pmc=7760631 |doi-access=free }}{{cite journal |last1=Kleinpeter |first1=Patricia |last2=Fend |first2=Laetitia |last3=Thioudellet |first3=Christine |last4=Geist |first4=Michel |last5=Sfrontato |first5=Nathalie |last6=Koerper |first6=Véronique |last7=Fahrner |first7=Catherine |last8=Schmitt |first8=Doris |last9=Gantzer |first9=Murielle |last10=Remy-Ziller |first10=Christelle |last11=Brandely |first11=Renée |last12=Villeval |first12=Dominique |last13=Rittner |first13=Karola |last14=Silvestre |first14=Nathalie |last15=Erbs |first15=Philippe |last16=Zitvogel |first16=Laurence |last17=Quéméneur |first17=Eric |last18=Préville |first18=Xavier |last19=Marchand |first19=Jean-Baptiste |title=Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition |journal=OncoImmunology |date=2 October 2016 |volume=5 |issue=10 |pages=e1220467 |doi=10.1080/2162402X.2016.1220467 |pmid=27853644 |pmc=5087307 }}
• The myvac® platform is based on an MVA vector which safety, biological activity and ability to induce an immune response against tumor antigens are established and recognized.{{Cite web|url=https://www.biospectrumasia.com/news/83/16873/transgene-nec-bostongene-collaborate-for-ovarian-and-head-neck-cancers-trials.html|title=Transgene, NEC, BostonGene collaborate for ovarian and head & neck cancers trials|website=www.biospectrumasia.com}} The platform enables the design of personalized viruses based on each patient’s tumor mutations.{{cite journal |last1=Bendjama |first1=Kaïdre |last2=Quemeneur |first2=Eric |title=Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer |journal=Human Vaccines & Immunotherapeutics |date=2 September 2017 |volume=13 |issue=9 |pages=1997–2003 |doi=10.1080/21645515.2017.1334746 |pmid=28846477 |pmc=5612284 }} Transgene selects around 30 neoantigens per patient, based on the AI of its partner NEC, and then encodes them into viral DNA.{{Cite web|url=https://www.nec.com/en/press/201810/global_20181030_02.html|title=NEC and Transgene announce a collaboration in the field of individualized cancer immunotherapy, leveraging NEC's AI and Transgene's myvac™ platform|website=NEC}}

The Company has several clinical-stage products in its portfolio.

1- TG4050 : This neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.{{Cite web |date=2023-06-11 |title=French cancer vaccine shows promise against recurrent tumours |url=https://www.rfi.fr/en/science-and-technology/20230611-transgene-french-cancer-vaccine-against-recurrent-tumours |access-date=2024-12-27 |website=RFI |language=en}}

2- TG4001 : is a therapeutic vaccine designed to express the E6 and E7 antigens of the HPV-16 virus (human papillomavirus type 16).{{Cite web|url=https://www.precisionvaccinations.com/vaccines/tg4001-hpv-cancer-vaccine|title = TG4001 HPV Cancer Vaccine}} Transgene is currently evaluating the full study results in detail to determine the best way forward for this program.{{Cite web |last=S.A |first=Transgene |date=2024-10-14 |title=Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers |url=https://www.globenewswire.com/news-release/2024/10/14/2962323/0/en/Transgene-Provides-Update-on-Phase-II-Trial-of-Therapeutic-Cancer-Vaccine-TG4001-in-Recurrent-or-Metastatic-HPV16-Positive-Cervical-and-Anogenital-Cancers.html |access-date=2024-12-27 |website=GlobeNewswire News Room |language=en}}

3- Oncolytic viruses: TG6050 and BT-001. Transgene’s oncolytic viruses are designed to directly and selectively destroy the cancer cells by using an oncolysis mechanism, while also inducing immune responses against tumor cells. In addition, during their replication, the virus expresses the payloads integrated in its genome and therefore allows the expression of immunomodulators and/or therapeutic agents specifically in the tumors{{cite journal |last1=Foloppe |first1=Johann |last2=Kempf |first2=Juliette |last3=Futin |first3=Nicolas |last4=Kintz |first4=Jacqueline |last5=Cordier |first5=Pascale |last6=Pichon |first6=Christelle |last7=Findeli |first7=Annie |last8=Vorburger |first8=Fabien |last9=Quemeneur |first9=Eric |last10=Erbs |first10=Philippe |title=The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism |journal=Molecular Therapy - Oncolytics |date=27 September 2019 |volume=14 |pages=1–14 |doi=10.1016/j.omto.2019.03.005 |pmid=31011628 |pmc=6461584 }}^,{{Cite web |title=First person enrolled in Phase I oncolytic virus trial |url=https://www.europeanpharmaceuticalreview.com/news/144632/first-person-enrolled-in-phase-i-oncolytic-virus-trial/}}^,{{ClinicalTrialsGov|NCT04725331|A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors}}^,{{Cite web |title=Regulatory actions for May 27, 2021 |url=https://www.bioworld.com/articles/507531-regulatory-actions-for-may-27-2021}}^,.{{Cite web |title=BioInvent presents proof-of-concept data on anti-FcyRIIB antibody BI-1607 at AACR Annual Meeting 2021 |url=https://www.biospace.com/article/releases/bioinvent-presents-proof-of-concept-data-on-anti-fcyriib-antibody-bi-1607-at-aacr-annual-meeting-2021/}}{{Cite web |last=S.A |first=Transgene |date=2024-11-07 |title=Transgene Reports Business, Pipeline and Financial Update for Q3 2024 |url=https://www.globenewswire.com/news-release/2024/11/07/2976950/0/en/Transgene-Reports-Business-Pipeline-and-Financial-Update-for-Q3-2024.html |access-date=2024-12-27 |website=GlobeNewswire News Room |language=en}}

4- Transgene and AstraZeneca have been collaborating since 2019 to co-develop oncolytic viruses from the Invir.IO™ platform.{{Cite news|url=https://www.reuters.com/article/us-transgene-deals-astrazeneca-idINKCN1S80EJ|title = AstraZeneca ties up with France's Transgene to develop viral immunotherapies|newspaper = Reuters|date = 2 May 2019}}{{Cite web|url=https://www.bioworld.com/articles/337225-transgene-s-armed-oncolytic-virus-technology-draws-az-in-potential-five-product-deal|title = Transgene's armed oncolytic virus technology draws AZ in potential five-product deal}}{{Cite web|url=https://www.biocentury.com/article/302035/astrazeneca-adds-oncolytic-virus-option-through-transgene-deal|title=AstraZeneca adds oncolytic virus option through Transgene deal}}

Transgene’s Management Committee is composed of the following members:

• Alessandro Riva, Chairman & Chief Executive Officer (CEO){{Cite news |title=Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio |url=https://www.businesswire.com/news/home/20230504006105/en/Transgene-Announces-New-Leadership-Structure-to-Accelerate-the-Development-of-its-Innovative-Immunotherapy-Portfolio |archive-url=http://web.archive.org/web/20230515011902/https://www.businesswire.com/news/home/20230504006105/en/Transgene-Announces-New-Leadership-Structure-to-Accelerate-the-Development-of-its-Innovative-Immunotherapy-Portfolio |archive-date=2023-05-15 |access-date=2024-12-26 |language=en}}
• Hedi Ben Brahim, Chairman & Chief Executive Officer (CEO);
• Éric Quéméneur, Executive Vice-President, Chief Scientific Officer (CSO);
• Christophe Ancel, Vice-President Pharmaceutical Operations & Qualified Pharmacist;
• Maud Brandely-Talbot, Vice-President Medical Affairs, Chief Medical Officer (CMO);
• Jean-Philippe Del, Vice-President, Chief Financial Officer (CFO);
• Thibaut du Fayet, Vice-President Corporate Development;
• John Felitti, Vice-President, General Counsel, Corporate Secretary;
• Gaëlle Stadtler, Vice-President, Human Resources Director.

{{reflist}}

• {{official website|https://www.transgene.fr/en/}}

Category:Mérieux family

Category:Biotechnology companies established in 1979

Category:Biotechnology companies of France

Category:Companies listed on Euronext Paris

Category:Life sciences industry

Category:Pharmaceutical companies established in 1979

Category:French companies established in 1979

Category:Pharmaceutical companies of France